Share on StockTwits
 

MedAssets (NASDAQ:MDAS) Director Terrence J. Mulligan sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $21.97, for a total transaction of $21,970.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

MedAssets (NASDAQ:MDAS) traded up 2.76% on Monday, hitting $21.94. 897,708 shares of the company’s stock traded hands. MedAssets has a 52-week low of $16.31 and a 52-week high of $26.58. The stock has a 50-day moving average of $21.11 and a 200-day moving average of $22.49. The company has a market cap of $1.357 billion and a P/E ratio of 254.17.

A number of research firms have recently commented on MDAS. Analysts at Citigroup Inc. initiated coverage on shares of MedAssets in a research note on Tuesday, February 18th. They set a “buy” rating on the stock. Separately, analysts at RBC Capital initiated coverage on shares of MedAssets in a research note on Thursday, February 13th. They set a “sector perform” rating and a $21.00 price target on the stock. Finally, analysts at Zacks upgraded shares of MedAssets from an “underperform” rating to a “neutral” rating in a research note on Monday, January 6th. They now have a $20.50 price target on the stock. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.68.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.